Intensive Monitoring Study on Tyvyt
Condition: Relapsed or Refractory Classical Hodgkin's Lymphoma Intervention: Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting
CONCLUSIONS: Our meta-analysis provided no overall evidence of an increased risk for both NHL and MM in subjects occupationally exposed to glyphosate. In secondary analyses we detected a small increase in risk for the category with highest level of exposure as well as for DLBCL. The evidence of publication bias suggests caution in the interpretation of the results. PMID: 32096774 [PubMed - in process]
Conclusion: HIV-HL with BM involvement identifies a very high-risk subpopulation in the post-ART era.
Publication date: Available online 27 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joanna M. Rhodes, Vincent LoRe, Anthony R. Mato, Elise A. Chong, Jacqueline C. Barrientos, James N. Gerson, Stefan K. Barta, Daniel J. Landsburg, Sunita Dwivedy Nasta, Jakub Svoboda, Alison W. Loren, Stephen J. Schuster
Publication date: Available online 27 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Arafat Ali Farooqui, Aqsa Ashraf, Talha Bin Farooq, Ahmad Anjum, Saif ur Rehman, Arshia Akbar, Abraham Kanate, Robert Dean, Malik Qistas Ahmed, Muhammad Junaid Tariq, Shaha Nabeel, Muhammad Salman Faisal, Faiz Anwer
Publication date: Available online 26 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Bridget K. Marcellino, Srdan Verstovsek, John Mascarenhas
Publication date: Available online 26 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): James T. England, Lalit Saini, Donna Hogge, Donna Forrest, Sujaatha Narayanan, Maryse Power, Thomas Nevill, Florian Kuchenbauer, Monika Hudoba, Artur Szkotak, Joseph Brandwein, David Sanford
In this study, our aim is to explore a rational combination of BCL-2 inhibitor plus Bruton's tyrosine kinase (BTK) blockade or p53 activation for treating DLBCL with the above characteristics. We demonstrated that a novel BCL-2 selective inhibitor APG-2575 effectively suppressed DLBCL with BCL-2 high expression via activating the mitochondrial apoptosis pathway. BTK inhibitor ibrutinib combined with BCL-2 inhibitors showed synergistic antitumor effect in DLBCL with mean expression of BCL-2 and myeloid cell leukemia-1 (MCL-1) through upregulating the expression level of BIM and modulating MCL-1 and p-Akt expression. For p53...
Publication date: March 2020Source: Human Pathology: Case Reports, Volume 19Author(s): Atif Saleem, Rohan Joshi, Li Lei, Lhara Lezama, Shyam S. Raghavan, Nastaran Neishaboori, Mohana Roy, Joe Schroers-Martin, Gregory W. Charville, Christian Kunder, Brent Tan, Beth A. Martin, Yasodha Natkunam
Publication date: March 2020Source: The Lancet Haematology, Volume 7, Issue 3Author(s): Motoharu Shibusawa
ConclusionRenal carcinomas in non-functional grafts are rare entities and most of them are diagnosed fortuitously. Despite the fact that these tumors are small, low grade and with a good prognosis, regular monitoring of non-functional grafts should be performed with at least an annual ultrasonography.